Shea & Trevas, Inc, Brandywine, Maryland, USA.
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Clin Infect Dis. 2021 Jun 1;72(11):e893-e900. doi: 10.1093/cid/ciaa1527.
Uptake of existing diagnostics to identify infections more accurately could minimize unnecessary antibiotic use and decrease the growing threat of antibiotic resistance. The Infectious Diseases Society of America (IDSA) and the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) agree that, to improve uptake of existing diagnostics, healthcare providers, health systems, and payors all need better clinical and economic outcomes data to support use of diagnostic tests over empiric use of antibiotics, providers need better tools and education about diagnostic tests, and diagnostics developers need federal funding in the absence of a viable diagnostics market. Recommendations from PACCARB and the IDSA are amplified. Incentives for-and challenges to-diagnostics research, development, and uptake are summarized. Advocacy opportunities are given for infectious disease professionals to join the fight against antimicrobial resistance.
为了更准确地识别感染,提高现有诊断方法的利用率可以最大限度地减少不必要的抗生素使用,并降低日益严重的抗生素耐药威胁。美国传染病学会(IDSA)和总统对抗抗生素耐药细菌顾问委员会(PACCARB)一致认为,为了提高现有诊断方法的利用率,医疗保健提供者、医疗系统和支付方都需要更好的临床和经济结果数据,以支持使用诊断测试而不是凭经验使用抗生素。此外,提供者需要更好的诊断测试工具和教育,而诊断方法的开发者则需要在缺乏可行的诊断市场的情况下获得联邦资金。PACCARB 和 IDSA 的建议得到了放大。本文总结了诊断研究、开发和采用的激励措施和挑战。为传染病专业人员提供了参与对抗抗菌药物耐药性的机会。